vTv Therapeutics Inc. (NASDAQ:VTVT) will be posting its quarterly earnings results on Tuesday, October 31st. Analysts expect vTv Therapeutics to post earnings of ($0.42) per share for the quarter.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.02. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.19 million. On average, analysts expect vTv Therapeutics to post $-1.21 EPS for the current fiscal year and $-1.53 EPS for the next fiscal year.

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) opened at 7.38 on Tuesday. vTv Therapeutics Inc. has a 52 week low of $3.57 and a 52 week high of $8.09. The company’s market cap is $71.53 million. The stock’s 50 day moving average price is $6.33 and its 200-day moving average price is $6.33.

TRADEMARK VIOLATION WARNING: “vTv Therapeutics Inc. (VTVT) Set to Announce Earnings on Tuesday” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/24/vtv-therapeutics-inc-vtvt-set-to-announce-earnings-on-tuesday.html.

In other news, major shareholder Ronald O. Perelman bought 10,000 shares of the stock in a transaction on Wednesday, August 16th. The shares were purchased at an average cost of $4.97 per share, for a total transaction of $49,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ronald O. Perelman bought 85,000 shares of the stock in a transaction on Friday, August 11th. The stock was purchased at an average price of $4.13 per share, for a total transaction of $351,050.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 165,000 shares of company stock worth $728,150. Corporate insiders own 0.80% of the company’s stock.

An institutional investor recently raised its position in vTv Therapeutics stock. State Street Corp raised its position in vTv Therapeutics Inc. (NASDAQ:VTVT) by 2.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,016 shares of the biotechnology company’s stock after buying an additional 1,976 shares during the quarter. State Street Corp owned about 1.01% of vTv Therapeutics worth $486,000 at the end of the most recent reporting period. Institutional investors own 11.05% of the company’s stock.

A number of analysts recently commented on the company. Zacks Investment Research lowered vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 19th. HC Wainwright set a $13.00 price target on vTv Therapeutics and gave the stock a “buy” rating in a report on Friday, August 4th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $15.00 price target on shares of vTv Therapeutics in a report on Friday, August 4th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $14.50.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.